Pathology Core for NF1 Research

NF1 研究的病理学核心

• 批准号: 7911618
• 负责人: Tilat Rizvi
• 金额: $ 6.16万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7911618
• 关键词: Animal Model; Animals; Antibodies; Autopsy; Blood specimen; Cells; Drug Kinetics; Evaluation; Harvest; Human; Human Cell Line; Human Virus; Injection of therapeutic agent; Maintenance; Malignant Neoplasms; Malignant Peripheral Nerve Sheath Tumor; Measurable; Measurement; Microscopic; Modeling; Monitor; Mus; Neurofibromatoses; Nude Mice; Organ; Pathology; Pharmaceutical Preparations; Pharmacodynamics; Quality Control; Relative (related person); Research; Services; Therapeutic; Tumor-Derived; Xenograft Model; Xenograft procedure; cost; design; gene therapy; human disease; member; therapeutic target; tumor; tumor growth; tumor xenograft; validation studies

The Xenograft Core for NF1 Experimental Therapeutics is designed to provide timely and cost-efficient access to animal models of neurofibromatosis-related cancers using human tumor derived cells. We have successfully established human xenograft models of malignant peripheral nerve sheath tumors (MPNSTs) in athymic nude mice. While xenograft models in general are considered to be less authentic relative to human disease then native, spontaneous tumor models, they have the advantage of being rapid, measurable and predictable. Another important advantage for some types of biologic therapeutic applications is that xenograft tumors are of human origin, and are therefore more appropriate for the study of agents directed at therapeutic targets that may differ in human and mouse cells (such as antibodies or gene-based therapies using human viruses). The Xenograft Core gives Cincinnati Center for Neurofibromatosis Research members access to expertise and services they would otherwise need to individually acquire, providing an economy of effort. Services include maintenance and quality control of human cell lines, mouse injections for tumor formation, drug administration, animal monitoring and serial measurements of tumor growth, serial blood sampling for pharmacokinetic studies, necropsy and harvesting of tumor and organs for microscopic evaluation and pharmacodynamic (target validation) studies.

NF1实验疗法的异种移植核心旨在提供及时和成本效益 使用人类肿瘤衍生细胞的神经纤维瘤病相关癌症的动物模型。我们有 成功地建立了恶性外周神经鞘肿瘤（MPNSTS）的人异种移植模型 无静脉裸鼠。虽然异种移植模型通常被认为相对于人类而言不那么真实 当时本地自发肿瘤模型的疾病，它们具有快速，可衡量和 可预测。某些类型的生物治疗应用的另一个重要优势是异种移植物 肿瘤是人类起源的，因此更适合于针对针对的药物的研究 可能在人和小鼠细胞中不同的治疗靶标（例如抗体或基于基因的疗法 使用人类病毒）。异种移植核心为神经纤维瘤病研究提供了辛辛那提中心 成员访问专业知识和服务，否则他们需要单独获取，提供 努力的经济。服务包括对人类细胞系的维护和质量控制，鼠标注射 肿瘤形成，药物给药，动物监测和肿瘤生长的系列测量 用于药代动力学研究，肿瘤和器官的药代动力学研究的血液采样 评估和药效学（目标验证）研究。